Premium
Mechanisms of action of fingolimod in multiple sclerosis
Author(s) -
Antel Jack
Publication year - 2014
Publication title -
clinical and experimental neuroimmunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 15
ISSN - 1759-1961
DOI - 10.1111/cen3.12079
Subject(s) - fingolimod , multiple sclerosis , neuroscience , immune system , medicine , sphingosine 1 phosphate , sphingosine , receptor , pharmacology , immunology , biology
Fingolimod is a sphingosine 1‐phosphate receptor ( S 1 PR ) modulator approved as a therapy for multiple sclerosis. The present review will describe how interactions of fingolimod with S 1 PR , can induce the dual effects of inhibiting signaling and functional responses induced by S 1 P , the natural ligand for the S 1 PR , while continuing itself to induce active signaling and functional responses. These dual effects of fingolimod will be considered in terms of their mechanisms of actions on the systemic immune system, the blood–brain barrier, and within the central nervous system.